Eris Lifesciences Limited has announced a strategic partnership with Natco Pharma Limited to commercialise Semaglutide in India. This move aims to bolster Eris’s leadership in the rapidly expanding diabetes and metabolic care market.
Semaglutide, a GLP-1 receptor agonist, is recognised globally for its effectiveness in managing Type 2 diabetes and chronic weight issues. The drug’s introduction is timely, as India faces a growing diabetic population and increasing awareness of obesity management. GLP-1 therapies, such as Semaglutide, present significant growth opportunities in the metabolic segment.
Eris Lifesciences has established a robust presence in the diabetology field, engaging extensively with specialists across India. The addition of Semaglutide is anticipated to enhance Eris’s portfolio in advanced diabetes therapies and expand its role in next-generation metabolic treatments.
The partnership leverages the strengths of both companies: Eris’s strong commercial presence and diabetes franchise, and Natco’s expertise in manufacturing and regulatory processes for complex formulations.
Strategic Partnership Details
Natco Pharma has secured approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic Semaglutide for the Indian market. The launch is expected in March 2026, targeting Type 2 diabetes management and addressing unmet needs in India’s metabolic care landscape.
Leadership Commentary
Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, stated, “Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies, we believe Eris is well positioned to drive rapid adoption and enhance patient access in India.”
Bakshi further noted that Eris has been preparing its commercial strategy to capitalise on the GLP-1 opportunity, viewing this partnership as a long-term value driver for the company.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).